Table 1.
Summary of published CAR-T trials with focus on CRS outcomes.
| References | Target | Lymphodepletion | CRS Scale | Total patients treated |
CRS Grade 1 or 2 |
CRS Grade 3 |
CRS Grade 4 |
CRS Grade 5 |
Additional comments |
|---|---|---|---|---|---|---|---|---|---|
| Lee et al. (14) | CD19 | Fludarabine/ Cyclophosphamide (Flu/Cy) | Trial specific | 21 | 10 | 3 | 3 | 0 | 4 patients received tocilizumab and/or steroids |
| Gardner et al. (22) | CD19 | Flu/Cy (n = 14) No lymphodepletion (n = 31) |
Trial specific | 45 | 33 | 10 | 16 patients received tocilizumab; 10 received steroids | ||
| Neelapu et al. (20) | CD19 | Flu/Cy | Lee | 101 | 82 | 9 | 3 | 1 | Grade 5 event was due to hemophagocytic lymphohistiocytosis. 43 patients received tocilizumab and 27 received steroids |
| O'Rourke et al. (79) | EGFRvIII | None | Not described | 10 | 0 | ||||
| Ramos et al. (46) | CD30 | None | Not described | 9 | 0 | ||||
| Schuster et al. (19) | CD19 | Cy-only (n = 10) Bendamustine (n = 8) RT + Cy (n = 4) Other (n = 6) |
Penn | 28 | 11 | 4 | 1 | 0 | 1 patient received tocilizumab; none received steroids |
| Fry et al. (42) | CD22 | Flu/Cy | Lee | 21 | 16 | 0 | 0 | 0 | |
| Maude et al. (17) | CD19 | Flu/Cy (n = 71) Cytarabine/Etoposide (n = 1) |
Penn | 75 | 23 | 16 | 19 | 0 | 28 patients received tocilizumab |
| Park et al. (18) | CD19 | Cy (n = 43) Flu/Cy (n = 10) |
MSKCC | 53 | 31 | 13 | 1 | 23 patients received tocilizumab and/or steroids | |
| Bishop et al. (80) | CD19 | Flu/Cy or bendamustine | Penn | 7 | 2 | 2 | 0 | 0 | |
| Cao et al. (81) | CD19 | Flu/Cy | Lee | 11 | 3 | 6 | 0 | 0 | All patients received anti-PD-1 ab therapy 3 days after CAR T cells. None required tocilizumab or steroids |
| Zhao et al. (82) | BCMA | Cy | Lee | 57 | 47 | 4 | 0 | 0 | 24 patients received tocilizumab. |